The present invention provides an improved process for preparing microparticles containing glatiramer acetate having low levels of residual organic solvent(s), in particular dichloromethane. The microparticles are incorporated into long acting parenteral pharmaceutical compositions in depot form that are suitable for subcutaneous or intramuscular implantation or injection, and that may be used to treat multiple sclerosis.

In one aspect, compositions are described herein. A composition described herein comprises a nanoparticle, a therapeutic species, and a linker joining the nanoparticle to the therapeutic species. The linker joining the nanoparticle to the therapeutic species comprises a Diels-Alder cyclo-addition reaction product. Additionally, in some embodiments, the nanoparticle is a magnetic nanoparticle.

Magnetosomes for use in a sequential laser radiation medical treatment, wherein the magnetosomes are administered to a body part of an individual. In a first step, the magnetosomes are irradiated by a laser radiation, and in a second step, the magnetosomes are irradiated by a laser radiation of lower power than in the first step or no laser irradiation of the magnetosomes is performed. The sequence of the first step and second step is repeated at least once.

The presently-disclosed subject matter relates to adsorptive radiocontrast constructs in multiple advantageous structural embodiments, which are designed to possess dual therapeutic and diagnostic actions. A concomitant therapeutic antiplatelet, as well as vasodilatation, effects, and a diagnostic real-time continuous visualization of an artery, can be obtained via direct injection of the constructs into said artery using a suitable catheter during procedural angiography with or without percutaneous intervention.

The present invention provides an improved process for preparing microparticles containing glatiramer acetate having low levels of residual organic solvent(s), in particular dichloromethane. The microparticles are incorporated into long acting parenteral pharmaceutical compositions in depot form that are suitable for subcutaneous or intramuscular implantation or injection, and that may be used to treat multiple sclerosis.

Disclosed is a composition comprising iron oxide magnetic particles. The composition is delivered to a liver in a hepatocyte-specific manner to minimize damage to other organs, and is safely excreted from a body within a few weeks. Further, the particles have excellent hepatocyte targeting ability, and thus are used as a liver cancer treatment agent and a hepatocyte targeting carrier.

The present invention relates to compositions and methods for delivering an oligonucleotide-functionalized nanoparticle.

Disclosed is a therapeutic patch for the gastrointestinal tract including a mucoadhesive material along with magnetic nanoparticles and a drug to be delivered to a living body, which are supported on the mucoadhesive material. A method of manufacturing the therapeutic patch for the gastrointestinal tract is also provided and includes preparing a mucoadhesive polymer, preparing a catechol precursor, mixing the mucoadhesive polymer and the catechol precursor, freeze-drying a mixture in the mixing step, mixing a powder resulting from the freeze-drying step with magnetic nanoparticles and a drug, and subjecting the resultant mixture to molding using a mold and then freeze-drying.

In one aspect, compositions are described herein. A composition described herein comprises a nanoparticle, a therapeutic species, and a linker joining the nanoparticle to the therapeutic species. The linker joining the nanoparticle to the therapeutic species comprises a Diels-Alder cyclo-addition reaction product. Additionally, in some embodiments, the nanoparticle is a magnetic nanoparticle.

Embodiments disclosed herein relate to magnetic nanoparticles having a non-narcotic analgesic, as well as methods of preparation and use thereof. A magnetically response pharmaceutical can include a core region having magnetic nanoparticles (MNPs) and a protein-based analgesic. Further, an exterior coating comprising a polymer can be formed around the core region. The magnetically responsive pharmaceutical can be administered to a recipient and directed to a target region using an external magnetic field.